First-in-human trial of AB-1002 designed to evaluate safety and preliminary efficacy in participants with New York Heart Association (NYHA) Class III heart failure Trial enrolled 11 participants in ...
Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...
Alector, Inc. is a pre-revenue biotech reset after Latozinemab’s Phase 3 failure, now trading at a deep discount. Nivisnebart, targeting Alzheimer’s, is ALEC’s next major catalyst; interim Phase 2 ...
The half-life of CK-586 was observed to be in the range of 14 to 17 hours. The data support the advancement of CK-586 to a Phase 2 trial for heart failure with preserved ejection fraction, expected to ...
Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure ...
BioCardia announces data verification completion for Phase 3 CardiAMP HF study on heart failure treatment, with results due March 30, 2025. BioCardia, Inc. has completed source data verification and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results